Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why I Think GlaxoSmithKline plc (GSK) Is So Much More Than Just an Income Stock

LONDON — With interest rates being at historic lows, stocks such as GlaxoSmithKline plc (LON:GSK) have offered a remedy for income-seeking investors.

Indeed, the shares currently yield an impressive 4.4% despite rising by more than 30% in the last three years alone. Clearly, it is understandable why the shares usually form a key part of many investors’ portfolios.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

However, pigeonholing GlaxoSmithKline plc (LON:GSK) as being little more than a source of income is, in my view, a tad unfair.

Of course, we all know the familiar story that the developed world has an ageing population, which will require treatments and health care in future on a larger scale than it currently does. This situation undoubtedly presents an opportunity for health care companies such as GlaxoSmithKline plc (LON:GSK).

However, the potential for share-price gains also exists over a much shorter investment horizon.

Unlike stable mate AstraZeneca plc (LON:AZN), GlaxoSmithKline plc (LON:GSK) has successfully managed its portfolio of patented blockbuster products. Indeed, it seems to have avoided a so-called patent cliff — where old patents expire, there are no new products to replace them, and revenue then declines significantly.

This year alone, GlaxoSmithKline plc (LON:GSK) is hoping to gain regulatory approval for a handful of potentially blockbuster treatments, with the latest positive news coming at the end of May when approval was obtained for two of the company’s medicines to treat advanced melanoma in patients with certain gene mutations.

Of course, approvals are not guaranteed but it appears as though the company is, in sporting terminology, throwing a lot of darts so that it has a good chance of hitting the bull’s-eye.

In addition, the shares currently trade on a P/E of 14.3 and offer fairly brisk earnings-per-share growth of around 6.5% per annum.

Although GlaxoSmithKline plc (LON:GSK)’s shares trade on a higher multiple than peers such as AstraZeneca plc (LON:AZN) and the market as a whole, I believe the potential for the company to deliver positive news flow means the shares remain attractive at the current price of 1,670 pence.

Even if the above is not enough to get your pulse racing, the shares sit at No. 19 in the top yielders of the FTSE 100 index. Buy them for an income, yes. Just don’t think that’s all you could be getting!

The article Why I Think GlaxoSmithKline Is So Much More Than Just an Income Stock originally appeared on and is written by Peter Stephens.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.